<DOC>
	<DOC>NCT00048217</DOC>
	<brief_summary>Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.</brief_summary>
	<brief_title>A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Completion T1249102; Currently failing a T20 containing regimen Noncompletion of T1249102.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>